Altimmune (NASDAQ:ALT) Earns Buy Rating from HC Wainwright

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 57.69% from the stock’s current price.

Several other brokerages have also commented on ALT. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. B. Riley reissued a “buy” rating and set a $20.00 price target on shares of Altimmune in a research report on Monday, August 12th. Finally, UBS Group assumed coverage on shares of Altimmune in a research report on Tuesday. They set a “buy” rating and a $26.00 price target for the company. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Stock Down 10.0 %

Shares of Altimmune stock opened at $7.61 on Thursday. The firm has a market capitalization of $541.22 million, a P/E ratio of -4.91 and a beta of 0.09. The company has a 50 day moving average price of $7.02 and a 200 day moving average price of $6.91. Altimmune has a 52 week low of $2.34 and a 52 week high of $14.84.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the previous year, the business earned ($0.39) earnings per share. As a group, research analysts anticipate that Altimmune will post -0.54 earnings per share for the current fiscal year.

Insider Transactions at Altimmune

In other news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the sale, the director now owns 41,958 shares of the company’s stock, valued at $289,510.20. This trade represents a 27.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its stake in Altimmune by 13.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock valued at $156,000 after acquiring an additional 1,821 shares during the period. Creative Planning grew its stake in Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after acquiring an additional 3,132 shares during the period. CANADA LIFE ASSURANCE Co acquired a new stake in Altimmune in the 1st quarter valued at $44,000. Charles Schwab Investment Management Inc. grew its stake in Altimmune by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after acquiring an additional 4,772 shares during the period. Finally, Larson Financial Group LLC acquired a new stake in Altimmune in the 3rd quarter valued at $31,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.